Published in Biochem Pharmacol on June 15, 1982
Solubilization and characterization of guanine nucleotide-sensitive muscarinic agonist binding sites from rat myocardium. Br J Pharmacol (1984) 0.89
Solubilized rabbit striatal A2a-adenosine receptors: stability and antagonist binding. Arch Biochem Biophys (1993) 0.81
Solubilization of dopamine-D2 receptors from synaptosomal membranes of the bovine caudate nucleus. Br J Pharmacol (1984) 0.77
Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci (1981) 3.71
Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci U S A (1991) 2.30
[3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol (1982) 2.25
Serotonergic component of neuroleptic receptors. Nature (1978) 1.74
Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol (1979) 1.65
In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole. Mol Pharmacol (1982) 1.48
Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol (1978) 1.40
Axonal transport of opiate receptors in capsaicin-sensitive neurones. Brain Res (1984) 1.23
Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol (1985) 1.21
Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J Med Chem (1999) 1.18
The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem (2001) 1.11
Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci (1989) 1.03
Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci Lett (1992) 1.02
Sodium-potassium ATPase inhibition potentiates compound 48/80-induced histamine secretion from mast cells. Br J Pharmacol (1984) 1.01
A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically. Br J Pharmacol (1993) 0.98
Solubilization of muscarinic acetylcholine receptors from mammalian brain: an analytical approach. Anal Biochem (1981) 0.94
Photoaffinity labeling of the monoamine transporter of bovine chromaffin granules and other monoamine storage vesicles using 7-azido-8-[125I]iodoketanserin. Biochemistry (1989) 0.93
Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain. Naunyn Schmiedebergs Arch Pharmacol (1986) 0.92
Two populations of neurotensin binding sites in murine brain: discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution. Eur J Pharmacol (1987) 0.92
Criteria for receptor sites in binding studies. Biochem Pharmacol (1984) 0.90
Stereospecific in vitro binding of [3H]dexetimide to brain muscarinic receptors. J Neurochem (1979) 0.88
Evidence for a localization of dopamine-beta-hydroxylase within the chromaffin granules. FEBS Lett (1975) 0.87
Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol (1988) 0.86
[RP 67580, a potent and selective substance P non-peptide antagonist]. C R Acad Sci III (1992) 0.86
Photoaffinity probes for serotonin and histamine receptors. Synthesis and characterization of two azide analogues of ketanserin. J Biol Chem (1985) 0.85
Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dendrotoxin I in the rat. Eur J Pharmacol (1991) 0.85
Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone. Life Sci (1978) 0.85
Muscarinic acetylcholine receptor: thermodynamic analysis of the interaction of agonists and antagonists. Biochim Biophys Acta (1986) 0.85
Spiperone: a ligand of choice for neuroleptic receptors. 3. Subcellular distribution of neuroleptic drugs and their receptors in various rat brain areas. Biochem Pharmacol (1978) 0.84
Distribution of neurokinin B in rat spinal cord and peripheral tissues: comparison with neurokinin A and substance P and effects of neonatal capsaicin treatment. Neuroscience (1992) 0.83
Different postnatal ontogeny of two [3H]neurotensin binding sites in rat brain. Brain Res (1987) 0.83
Absence of dopamine and muscarinic receptors on human lymphocytes. Arch Int Pharmacodyn Ther (1982) 0.83
Riluzole, a glutamate antagonist, enhances slow wave and REM sleep in rats. Neurosci Lett (1988) 0.83
Axonal transport of TREK and TRAAK potassium channels in rat sciatic nerves. Neuroreport (2000) 0.82
Interleukin-1 beta induces long-term increase of axonally transported opiate receptors and substance P. Neuroscience (1995) 0.82
Spiperone: a ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs. Biochem Pharmacol (1978) 0.81
Preferential decrease in dopamine utilization in prefrontal cortex by zopiclone, diazepam and zolpidem in unstressed rats. J Pharm Pharmacol (1990) 0.81
Tissue fractionation in rat brain, kidney and liver. I. Intracellular localization of a 5-methyltetrahydrofolic acid requiring enzyme. Biochimie (1975) 0.81
Polyclonal antibodies against the rat NK1 receptor: characterization and localization in the spinal cord. Neuroreport (1992) 0.81
Solubilization of serotonin receptors from rat frontal Cortex. Biochem Pharmacol (1980) 0.80
In vivo binding of [3H]ketanserin on serotonin S2-receptors in rat brain. Eur J Pharmacol (1982) 0.80
Trapping of labelled ligands in intact cells: a pitfall in binding studies. Biochem Pharmacol (1983) 0.80
Axonal transport of receptors: coexistence with neurotransmitter and recycling. Biochem Pharmacol (1984) 0.80
Different subcellular localization of neurotensin-receptor and neurotensin-acceptor sites in the rat brain dopaminergic system. J Neurochem (1988) 0.80
IL-1 beta-like Freund's adjuvant enhances axonal transport of opiate receptors in sensory neurons. Neurosci Lett (1994) 0.80
[3H]Batrachotoxinin A 20-alpha-benzoate binding to sodium channels in rat brain: characterization and pharmacological significance. Eur J Pharmacol (1986) 0.80
Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone. Psychopharmacol Ser (1987) 0.79
Rapid agonist-induced decrease of neurotensin receptors from the cell surface in rat cultured neurons. Biochem Pharmacol (1991) 0.79
Short-term disappearance of muscarinic cell surface receptors in carbachol-induced desensitization. FEBS Lett (1983) 0.79
Separation of three cyclic-nucleotide-phosphodiesterases from bovine aorta. Biochem Biophys Res Commun (1978) 0.79
Regional and cortical laminar distributions of serotonin S2, benzodiazepine, muscarinic, and dopamine D2 receptors in human brain. J Neurochem (1984) 0.79
Functional characterization and potential applications for enhanced green fluorescent protein- and epitope-fused human M1 muscarinic receptors. J Neurochem (1999) 0.79
Fluorescent muscarinic EGFP-hM1 chimeric receptors: design, ligand binding and functional properties. J Recept Signal Transduct Res (1999) 0.79
Characterization of solubilized serotonin (S2) receptors in rat brain. Mol Pharmacol (1982) 0.79
Differential photoaffinity labelling of serotonin-S2 receptors and histamine-H1 receptors using 7-azidoketanserin. FEBS Lett (1985) 0.79
Distinction between dopaminergic and serotonergic components of neuroleptic binding sites in limbic brain areas. Biochem Pharmacol (1979) 0.79
Solubilized serotonin receptors from rat and dog brain. Selective labelling with [3H]ketanserin. FEBS Lett (1982) 0.79
Pharmacology and biochemistry of haloperidol. Proc R Soc Med (1976) 0.78
RP 62203, a 5-hydroxytryptamine2 antagonist, enhances deep NREM sleep in rats. Sleep (1992) 0.78
Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia nigra after retrograde axonal transport. Neuroscience (1992) 0.78
Temperature-dependence and heterogeneity of muscarinic agonist and antagonist binding. Biochem Pharmacol (1987) 0.78
Identification of the serotonin-S2 receptor ligand binding site by photoaffinity labelling with 7-azido-8-[125I]ketanserin ([125I]AZIK). FEBS Lett (1987) 0.78
Riluzole antagonizes the anxiogenic properties of the beta-carboline FG 7142 in rats. Psychopharmacology (Berl) (1989) 0.78
Impaired axonal transport of opiate and muscarinic receptors in streptozocin-diabetic rats. Brain Res (1986) 0.78
Antinociceptive properties and inhibition of neurogenic inflammation with potent SP antagonists belonging to perhydroisoindolones. Regul Pept (1993) 0.78
Differential effects of the isomers of tetramisole on adrenergic neurotransmission in cutaneous veins of dog. J Pharmacol Exp Ther (1977) 0.78
Muscarinic receptor: multiple sites or unitary concept? Arch Int Pharmacodyn Ther (1981) 0.78
Retrograde axonal transport of neurotensin in rat nigrostriatal dopaminergic neurons. Modulation during ageing and possible physiological role. Biochem Pharmacol (1994) 0.78
Is the sigma 2 receptor in rat brain related to the K+ channel of class III antiarrhythmic drugs? Eur J Pharmacol (1993) 0.77
Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy. Mov Disord (1988) 0.77
Retrograde axonal transport of receptor-bound opiate in the vagus and delayed accumulation in the nodose ganglion. Brain Res (1985) 0.77
Differentiation of solubilized dopamine receptors from spirodecanone binding sites in rat striatum. FEBS Lett (1980) 0.77
Solubilization of 3H-spiperone binding sites from rat brain. Life Sci (1978) 0.77
Neuroprotective effects of colchicine in the gerbil model of cerebral ischaemia. Neurosci Lett (1994) 0.77
Interaction of the substance P receptor antagonist RP 67580 with the rat brain NK1 receptor expressed in transfected CHO cells. Eur J Pharmacol (1993) 0.77
Benzodiazepine receptors in normal human brain, in Parkinson's disease and in progressive supranuclear palsy. Brain Res (1988) 0.77
Striatal injection of neurotensin increases tyrosine hydroxylase mRNA in substantia nigra. Ann N Y Acad Sci (1992) 0.77
Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor. J Med Chem (1990) 0.77
7-Amino-8-[125I]-ketanserin ([125I]AMIK), a highly sensitive, serotonin-S2 receptor ligand. Biochem Pharmacol (1986) 0.76
Presynaptic heteroreceptors in regulation of neuronal transmission. Biochem Pharmacol (1985) 0.76
[3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol (1988) 0.76
[3H]Desipramine and [3H]imipramine binding are not associated with noradrenaline and serotonin uptake in the brain. Eur J Pharmacol (1982) 0.76
Light and electron microscopic localization of retrogradely transported neurotensin in rat nigrostriatal dopaminergic neurons. Neuroscience (1992) 0.76
Down-regulation of 3H-lofentanil binding to opiate receptors in different cultured neuronal cells. Naunyn Schmiedebergs Arch Pharmacol (1989) 0.76
Axonal transport of dopamine-containing vesicles labelled in vivo with [3H]reserpine. Eur J Neurosci (1993) 0.76
Effects of some derivatives of 2-aminotetralin on dopamine-sensitive adenylate cyclase and on the binding of (3H)haloperidol to neuroleptic receptors in the rat striatum. Biochem Pharmacol (1978) 0.76
N-methylation of biogenic amines. I. Characterization and properties of an N-methyltransferase in rat brain using 5-methyltetrahydrofolic acid as the methyl donor. Biochem Pharmacol (1974) 0.76
Receptor binding properties in vitro and in vivo of some long-acting opiates. Arch Int Pharmacodyn Ther (1978) 0.76
Postnatal ontogeny of the rat brain neurotensin receptor mRNA. Neurosci Lett (1993) 0.76
Failure of a peripheral dopaminergic marker in Parkinson's disease. J Neurol Neurosurg Psychiatry (1983) 0.75
Axonal transport of muscarinic receptors in vesicles containing noradrenaline and dopamine-beta-hydroxylase. FEBS Lett (1984) 0.75
Autoradiographic localization of retrogradely transported neurotensin in nigrostriatal neurons. Ann N Y Acad Sci (1992) 0.75
Ethanol and opiate decrease the axonal transport of substance-P like immunoreactive material in rat vagus-nerves. Neuropeptides (1990) 0.75
Presynaptic receptors: more hetero than auto. Trends Pharmacol Sci (1998) 0.75
Effect of ATP upon dopamine-beta-hydroxylase. Biochem Pharmacol (1975) 0.75
Effect of gamma-butyrolactone on the retrograde axonal transport of neurotensin in dopaminergic neurones. Eur J Pharmacol (1990) 0.75
A serotonergic component of neuroleptic receptors. Arch Int Pharmacodyn Ther (1977) 0.75
Is the low incidence of extrapyramidal side-effects of antipsychotics associated with antimuscarinic properties? J Pharm Pharmacol (1978) 0.75